A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease

NeuroReport

Volumn 8, Issue 3, 1997, Pages 669-672

  Newman, Danielle D ^c   Rajakumar, Nagalingham ^c   Flumerfelt, Brian A ^c   Stoessl, A Jon ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

dynorphin; levodopa; Parkinson's disease; rotation; sensitization; substantia nigra; opioid receptor

Indexed keywords

APOMORPHINE; BENSERAZIDE; KAPPA OPIATE RECEPTOR; LEVODOPA; NORBINALTORPHIMINE; OPIATE ANTAGONIST; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SENSITIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

EID: 0030934249     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199702100-00018     Document Type: Article

References (24)

1. Marsden CD and Parkes JD. Lancet i, 345-349 (1977).
2. Mouradian MM, Juncos JL, Fabbrini G et al. Ann Neurol 22, 475-479 (1987).
3. Mouradian MM, Juncos JL, Fabbrini G et al. Ann Neurol 24, 372-378 (1988).
4. Juncos JL, Engber TM, Raisman R et al. Ann Neurol 25, 473-478 (1989).
5. Gerfen CR, Engber TM, Mahan LC et al. Science 250, 1429-1432 (1990).
6. Chavkin C, James IF and Goldstein A. Science 215, 413-415 (1982).
7. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Sydney: Academic Press (1986).
8. Enger TM, Susel Z, Juncos JL et al. Eur J Pharmacol 168, 291-298 (1989).
9. Jellinger KA. Mol Chem Neuropathol 14, 153-197.
10. Gnanalingham KK and Robertson RG. Brain Res 640, 185-194 (1994).
11. Engber TM, Boldry RC, Kuo S et al. Brain Res 581, 261-268 (1992).
12. Engber TM, Susel Z, Kuo S et al. Brain Res 552, 113-118 (1992).
13. Matsumoto RR, Brinsfield KH, Patrick RL et al. J Pharmacol Exp Ther 246, 196-203 (1988).
14. Arnt J and Scheel-Kruger. J Psychopharmacol 62, 267-277 (1979).
15. Kilpatrick NC and Starr MS. Eur J Pharmacol 69, 407-419 (1981).
16. Olianos MC, De Montis GM, Mulas G et al. Eur J Pharmacol 49, 233-241 (1978).
17. Engber TM, Boldry RC and Chase TN. Eur J Pharm 200, 171-173 (1991).
18. Mansour A, Lewis ME, Khachaturian J et al. Brain Res 399, 69-79 (1986).
19. Mansour A, Fox CA, Akil H et al. Trends Neurosci 18, 22-29 (1995).
20. Miller WC and DeLong MR. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MA and Jarayaman A, eds. The Basal Ganglia, II, Structure and Function - Current Concepts. New York: Plenum Press, 1987: 395-413.
21. Mitchell IJ, Clarke CE, Boyce S et al. Neurosci 32, 213-226 (1989).
22. Robledo P and Feger J. Brain Res 518, 47-54 (1990).
23. Kitai ST and Kita H. Anatomy and physiology of the subthalamic nucleus: a driving force of the basal ganglia. In: Carpenter MA and Jarayaman A, eds. The Basal Ganglia, II, Structure and Function - Current Concepts. New York: Plenum Press, 1987: 357-373.
24. Maneuf YP, Mitchell OJ, Crossman AR et al. Brain Res 683, 102-108 (1995).